Opendata, web and dolomites

COMBACTE-CDI SIGNED

Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 COMBACTE-CDI project word cloud

Explore the words cloud of the COMBACTE-CDI project. It provides you a very rough idea of what is the project "COMBACTE-CDI" about.

interventional    actively    collaborative    merger    proof    laboratory    healthcare    platform    imi2    drivers    definition    true    prevalent    difficile    usually    contemporaneous    strain    lab    diagnostic    wps    burden    collected    provision    packages    economic    data    followed    isolates    expertise    bacterial    excellent    parallel    efpia    wp4    optimize    imi    evaluation    single    prior    executing    examined    experts    brings    infection    antibiotics    comprising    animal    options    frequency    sensitivity    market    feasible    exposed    individuals    effectiveness    settings    health    costeffectively    harmonise    resource    underestimated    diagnostics    limited    variations    strategies    surveillance    assay    morbidity    community    mean    link    trial    poses    wp2    reduce    multiple    successfully    resilience    models    lack    simulation    quantify    guidelines    diagnosis    bacte    food    create    compare    questionnaire    mortality    treatment    scientific    clinical    identification    euclid    incidence    infections    countries    combacte    size    accurate    notably    interrelated    conduct    aid    recurrence    clin    realization    hospitalized    playing    human    prevention    transmission    time    wp3    partnered    patients    input    clustering    epidemiological    impacts    authorization    provides    extensive    roles    ecdis    interventions    economy    resistance    therapeutic    combating    network    enhanced    synergistic    epidemiology    net    first    quantification    clostridium    wp1    citizens    cdi    sensitive    patient    subjects    practices    undertaken   

Project "COMBACTE-CDI" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Organization address
address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX
website: www.umcutrecht.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://www.combacte.com/about/combacte-cdi-understanding-of-the-epidemiology-and-clinical-impact-of-clostridium-difficile-infection/
 Total cost 4˙179˙307 €
 EC max contribution 2˙312˙305 € (55%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2016-09-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2020-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) coordinator 350˙255.00
2    UNIVERSITY OF LEEDS UK (LEEDS) participant 1˙330˙476.00
3    KLINIKUM DER UNIVERSITAET ZU KOELN DE (KOELN) participant 151˙848.00
4    ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO IT (ROMA) participant 150˙260.00
5    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 137˙676.00
6    NACIONALNI LABORATORIJ ZA ZDRAVJE, OKOLJE IN HRANO SI (MARIBOR) participant 90˙557.00
7    UNIVERSITEIT ANTWERPEN BE (ANTWERPEN) participant 58˙556.00
8    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 42˙676.00
9    ASTRAZENECA AB SE (SODERTAELJE) participant 0.00
10    BIOMERIEUX SA FR (Marcy l'Etoile) participant 0.00
11    DA VOLTERRA SAS FR (PARIS) participant 0.00
12    GLAXOSMITHKLINE BIOLOGICALS SA BE (RIXENSART) participant 0.00
13    PFIZER LIMITED UK (SANDWICH) participant 0.00
14    SANOFI PASTEUR SA FR (LYON) participant 0.00

Map

 Project objective

Clostridium difficile infection (CDI) is one of the most prevalent healthcare associated infections, affecting both hospitalized patients and individuals in the community; notably, there is an increasing realization that cases also occur in subjects not recently exposed to healthcare interventions, including antibiotics. CDI poses an extensive burden of morbidity, mortality and healthcare resource utilization, and so requires effective prevention and management strategies. Epidemiological data are, however, limited and studies typically have examined only part of a healthcare economy and usually have been focused on single countries/healthcare systems. Thus, there is a lack of robust, comprehensive data on the impact of CDI across countries in Europe. Furthermore, we know that large variations in the frequency of testing and the sensitivity of CDI diagnostics across European countries mean that the size of the problem is underestimated.

Combating Bacterial Resistance in Europe-CDI (COMBACTE-CDI) therefore aims to develop a detailed understanding of the epidemiology and clinical impact of CDI across multiple European countries. Our project proposal provides a collaborative approach comprising three scientific work packages (WPs). A large epidemiology study will be undertaken across Europe in WP1 to quantify the burden of CDI (incidence, distribution, recurrence, morbidity, mortality, transmission) across the whole healthcare economy. This will be followed by a case/control study in WP2, which along with data collected in a questionnaire will enable the consortium to assess current practices in Europe (guidelines, testing, surveillance, treatment, cost) and their potential impacts. WP3 will create a rich, European, research platform that will provide support for future proof-of-concept and clinical studies of new prevention and treatment strategies for CDI. The three interrelated research WPs will be supported by a management work package (WP4).

COMBACTE-CDI will harmonise with many of the IMI2 objectives; specifically, we aim to improve the health of European citizens by providing evidence of the true epidemiology and transmission of CDI. We will also develop ‘best-practice’ models for diagnosis, treatment and surveillance, which should reduce the incidence and impact of CDI (including mortality) across Europe, and will optimize patient management. Notably, in order to deliver these aims costeffectively and to test the resilience of our data, we will actively link and compare our data with other European projects that include CDI as a target condition. This synergistic approach will be all the more feasible as the participants in COMBACTE-CDI are playing key roles in multiple, relevant, parallel European CDI activities.

Our ambitious proposal aims to go beyond the state of the art in 8 aspects: quantification of CDI in the whole healthcare economy; contemporaneous comparison with animal and food isolates with those within human health; identification of potential drivers of strain clustering, providing enhanced information to aid further trial/study design and conduct; use of a novel highly sensitive diagnostic assay for more accurate CDI case definition; provision of both cost-effectiveness and transmission models to enable further evaluation of interventions; and finally, by comparing overall costs in different European healthcare settings, we will, for the first time, allow simulation of the economic impact of novel CDI treatment options, even prior to market authorization.

COMBACTE-CDI is the merger of excellent European expertise on the clinical, diagnostic, and therapeutic issues related to CDI and the expertise and input of 7 EFPIA partners. It brings together experts that partnered in CDI projects (EUCLID, ECDIS-NET), the largest existing (IMI-funded) clinical and laboratory network in Europe (CLIN-Net and LAB-Net) for successfully executing challenging epidemiological and interventional studies related to bacte

 Deliverables

List of deliverables.
Report on heterogeneity of testing and delivery of dataset Documents, reports 2020-02-13 13:11:22
Report on current treatment pathways Documents, reports 2020-02-13 13:11:11
Report on high risk groups and delivery of dataset Documents, reports 2020-02-13 13:11:32
Report on recurrent CDI, morbidity and mortality and delivery of dataset Documents, reports 2020-02-13 13:09:19
Report on current surveillance practices Documents, reports 2020-02-13 13:08:54
Report on current guidelines for diagnosis, management and control of CDI Documents, reports 2020-02-13 13:09:23
Report on strain distribution and delivery of dataset Documents, reports 2020-02-13 13:09:02
Full ethical approval of final study protocol from all countries Documents, reports 2020-01-28 14:45:03
Adaptation of COMBACTE website to include COMBACTE-CDI Websites, patent fillings, videos etc. 2020-01-28 14:45:03

Take a look to the deliverables list in detail:  detailed list of COMBACTE-CDI deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COMBACTE-CDI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COMBACTE-CDI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More